was you, look and we record making growth EXPAREL for Pacira EXPAREL reported Susan. year been. opportunities see Thank before as We stronger ever XXXX for and Pacira. for beyond, revenues to we've XXXX And financially an us tremendous outstanding us. than ahead we
management mounting effects you by and patients’ payers our all in ranging is midst quality crisis change an systems alike our practices. healthcare pain As and to opioid social wide the with driving of solutions country of life, consequences and address devastating epidemic Government, economic the to know, on communities. in mandating are significant
abuse opioids. the EXPAREL non-opioid stem and be is tide planned reducing are only solution pain, on to while fight and Strategically, single on acting continuum. uniquely a analgesic a management growth in block Pacira the indications. clinically for with playing of multiple misuse is EXPAREL postsurgical brachial the across existing or comprehensive role opioid the proven broader we robust trajectory a pain focused managing the eliminating As block, field long to forefront and of at for nerve local approved dose plexus infiltration, positioned
the position health to goal aim non-opioid pillars. advance evolve further leadership we and operating For We core leveraging by regenerative can to this solid competencies solutions. that innovative our providing management in growth three believe foundation our we pain achieve
First, in the settings. continuing of key surgical EXPAREL expansion
new DepoFoam partnerships pursuing third, platform and assets to infrastructure acquisitions products, leveraging And with and EXPAREL rapidly that or align advance and our complement audiences. clinical commercial targeting candidates. Second, physician innovative our strategy our directly technologies
begin with me Let EXPAREL.
deliver XX% We XXXX thrilled to expected momentum we seeing are million. are with net are to the to robust $XXX and in least at with by we year-over-year sales growth well-positioned increase
at and blocks are and influential medical group the management and varying such than foundation implement non-opioid at approach our procedure more facilitate perioperative enthusiasm programs triggered organizations they partnership a a professionals. XXXX, care. strong look, a specialty patients’ across approaches back EXPAREL our the recovery. with post-surgical a Johnson, improve peripheral growing delivering the complications to multimodal opioid-sparing Taking solutions. field world while standard integration closer key academic orthopedic at excellence, of to of ongoing healthcare that integrating develop for is And level well regional the X,XXX Together, our of of by centers After is launch, in often as that improve They comprised look is its performance involve three Recovery through is the nerve team and ERAS from engagement utilize or leading as postsurgical Two, EXPAREL typically Surgery as drivers approaches anesthesiologists. are costs. or pain and recovery, patient-centered of Anesthesia healthcare of becoming this MEDNAX, standardized a three, experience for and by regional strategy. nerve patient continues reducing the multi-disciplinary and support by led pain national a These anesthesiologists. faster of significant Enhanced innovation management impressive surgical the opioids core educational uptake and Johnson which blocks we One, As working gold procedural protocols forefront as results. synergistically & the protocols, block class
ERAS MEDNAX of partnership a as with Our core is we are the of EXPAREL example the role great expanding how of procedure-specific protocols.
volume features transversus transversus the involves implement abdominal in we for targeted collaborative EXPAREL plane EXPAREL between We maternal-fetal of or for anesthesia abdominis opioid-free how management. an perioperative guidance. muscle ground A TAP sections lasting field using to are as TAP Through working and team ultrasound plane the the long expanded new we nurses internal are infiltration breaking an MEDNAX oblique with cesarean of are innovative obstetricians a specialists, platform anesthesiologists, block our with muscle that customers. with with saline interacting in into the block terms and this pain
We're management protocol establishing with as ERAS minimization strategies the Centers in These this procedures. We ERAS from of opioid ambulatory comparative More successful will Excellence. hospitals practice practice are a excited companies and Pacira. implement where also ourselves and driving next initiating building of as inpatient certified educational national months. programs be are ERAS be to and out on interest the to collaborative initiative couple consulting go-to-partner national for for best
wins mode we anesthesia high from community launch the Our continues reporting they block. level a space. see squarely the engagement for remain field-based daily brachial plexus of are a in nerve Of and within team enthusiasm and to note,
the block seeing customer in are the size and added X,XXX active growth with We of our base nearly steady nerve accounts new launching strong indication. since
multimodal widely approaches regional administrators. benefits of as literature field the surgeons, and feature a upside, to eliminating accepted for and regional and surgery. by nerve blocks, along regimen blocks great during with see become continues The anesthesiologists, patients more pain we So after
and targeted pain importantly, and a long-acting EXPAREL and pain of use preventing in while like pain significant postoperative proven at avoiding use retention, With is improved days clinically decreased technologies vomiting, satisfaction. the catheters and effects Most complications as pumps. such single-dose and block, stay, nausea, in costly reduced patient eliminating length region directly urinary of provides the in and opioid EXPAREL resulting statistically being costs, providing improvement delirium, while side analgesia control, relief, of cumbersome delivery fewer of
hysterectomy full use observing expand used tissue we're come triggering anesthesiologists regional with across to field be colorectal blocks soft including be the to and -- bariatric their are plexus circle, as experiences multiple which block, successful to used surgeries which C-Section brachial nerve can Finally, can broadly procedures. across such TAP
reduction we Society Phase The consumption post-surgical XX of peer-reviewed value pain recently has a opioid total or achieved study for P through Anesthesia C-Section, from block with and results scores announced TAP to of later TAP the in intensity significant with of compare literature and presentation we a submitted for a EXPAREL less to top-line this study and X For hours than EXPAREL publication SOAP that block plan bupivacaine. with Meeting Perinatology results submit positive a our & year. Annual Obstetric been the medical to study X.XX. at full statistically the
solutions resources the J&J's partnership solutions through on and behind & course The healthcare EXPAREL, and thousands as including with EXPAREL J&J marshaled procedures team programs substantial which fractures. for component important passion carried EXPAREL procedural rotator front, delivering integrating has of hip of cuff, as continues and class attract such uptake Finally including Johnson orthopedic our across EXPAREL tremendous widely Johnson commercial for providers world educational and non-opioid spine opioid-sparing medical of key shared reach. a our out their procedural J&J's to mutual drive
ahead, EXPAREL is in XXXX. shape for Looking terrific
as driving EXPAREL growth catalyst a We success inpatient XXXX opportunities, shifting including are using the by focused on multiple building procedures to on setting. our for outpatient
opportunity for Xst, the we code crucial effective the Dental that product-specific provides our payment option. $X.XX element code at significant January follow see opioids providing here with and provides for to reimbursement rates. to EXPAREL a billing XX% growth for used the Through Services on us and Association procedures. ambulatory reimbursement and sustained ASCs effect Last this payers for therapeutic may Xst time of In of up business, our code parallel, surgery Medicare January are or use CXXXX, infiltration without first Consequently, As reimbursement with commercial Centers per in in milligram and center an adults American took or of Medicare's year, to drug for the sets wisdom surgical Medicaid new exposed EXPAREL oral lead when young setting. the expanding release is tooth implemented of team also on reimburse This the code you which separate and roughly was EXPAREL working ambulatory Many a national following CMS Medicare made non-opioid recall, began reimbursement ASC. this Medicare for in reimbursement. teens a and extraction.
populations. like to -- non-opioid to is these access a having critical EXPAREL option vulnerable for non-opioid So
Medicaid as level National large high from dental Aetna, Plan national a payers regional a EXPAREL Dominion use oral maxillofacial like seeing as payer, are We engagement the even procedures. with covering Dental payers well dental Connecticut for a of of and
While changes leading reimbursement by centers, and cover the I Human public settings. report oral the slide December after key both drivers is these Services business. with to early it submit highly The it’s now possible positive EXPAREL days, as finalize whenever non-opioids might The Department the Congress. This Pain indicators both of outpatient of their is surgery are and the line on last use report will in the taskforce XX-day of issued around still ambulatory landscape period, the guidance first and favorable Health quickly and the new Taskforce. Management therapy which recommends in report reimbursement in comment
our significant flexibility pillar technology for a pain the approaches now opioid managing crisis the sub-acute pain. for acute, DepoFoam leveraging ability opioids Turning unmet Eliminating applications. customized safety, second epidemic. address proven by our triggered was of of current need The tools to new strategic not will pain and growth, and for and chronic
and have the Following to feasibility into studies, clinic. advance two programs readouts we rapidly from DepoFoam-based selected preclinical
acute a or anesthetic, other subarachnoid bupivacaine and pain. First, intrathecal chronic the than delivery for DepoFoam-based of local
the the Here of typically we to delivered use or to catheters. and opportunity opioids pumps an subarachnoid intrathecal alternative by have provide
than DepoFoam successfully with connection previously marketed meningitis. for with DepoCyt experience have cytarabine was as We the our here years technology or for the in technology in substantial product setting intrathecal lymphomatous used the more XX
neurocognitive effects end dexmedetomidine offer compound effects has and acuity also the pain extended we to with and has and We a painful life, market patients as conditions the fewer delivery second selected Dexmedetomidine Depo-dexmedetomidine. of pain delirium analgesic therapeutic dose have has while product, is believe we providing the and properties the in adequate The clinical of reduced of sedative With quality opioid-sparing other a It control. demonstrated elderly. sedatives. versus see potential the life this mental of also elderly. complementary in targeted
uses. in we formulations invest no current clinical DepoMeloxicam, have with program landscape in longer made this therapeutic oral given for for the clinic As decision the a to similar strategic competitive
to evolving on move our providing innovative health regenerative non-opioid third let's growth, pillar leadership Finally, and of solutions. and our
As see the discussed we’ve on building we a patient portfolio pathway. along previously, opportunity neural in journey improving differentiated a the focused non-opioid vast
to believe opportunities calling in surgical aim There are the present treatment tremendous complementary average continuum, in full us are a and on pursuing to We several technologies to of an along audiences and anesthesia is enhance and pain months of with to osteoarthritis, We orthopedic to non-opioid regenerative XX we today. approach. the To outcomes provide to opioid of surgery for control great additional this non-opioid pre-debilitation them are take provide experience osteoarthritis thoughtfully surgery highly the osteoarthritis innovative the case of onset can spine, of EXPAREL roughly time with we advance opportunities surgical from and are products patients replacement that our free. the surgery pain patients allow surgical interest solutions we the to with States. years pain In greatly and intervention. in as knee example, well and United
financial for We and are be significant and partner clinical commercial hospital to the opioid-sparing and track proven strategies. expertise record our partnership to the to in improving choice, well-positioned market of network partner ambulatory deep markets, given -- strength, access
possible. and Rich provide ahead, With as that to an activities. on for advancing committed to turn an strategy our overview, Rich? executing to our I'll patients opioid look call regulatory over to alternative as the mission update many As clinical providing and remain our we we
